Sign In
Buy QTRX
$3.48
-0.0400 (-1.14%)
At Close: Jul 31, 2026
Quanterix: Trading Below 1x Sales Despite A Changing Story
12:18pm, Monday, 20'th Jul 2026
Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. QTRX targets cash flow breakeven in H2 2026, leveraging c
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 16'th Jul 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 16'th Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:22am, Wednesday, 10'th Jun 2026
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
08:03am, Tuesday, 09'th Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
09:00am, Thursday, 04'th Jun 2026
Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
08:02am, Thursday, 04'th Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
08:01am, Wednesday, 03'rd Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that s
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 26'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery
Quanterix Announces Planned Transition of Chief Financial Officer
04:01pm, Tuesday, 12'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that V
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
07:21pm, Wednesday, 06'th May 2026
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
06:25pm, Wednesday, 06'th May 2026
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.53 per share a year ago.
Quanterix Releases Financial Results for the First Quarter of 2026
04:01pm, Wednesday, 06'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
08:00am, Wednesday, 06'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading
